Prostaglandin A2 at low rates of infusion restores the antidiuretic effect of vasopressin in lithium-treated rats.
To test the effect of prostaglandin A2 (PGA2) on renal function, infusions of PGA2 (0-7 ng/kg/min), arginine-vasopressin (AVP) (1-25 ng/kg/min) and PGA2 plus AVP were administered to male rats made resistant to the antidiuretic effect of AVP by pre-treatment with lithium. In non-lithium-treated control rats, AVP had its expected antidiuretic action but in lithium-treated rats neither urinary volume nor osmolarity was changed. Prostaglandin A2 alone had no effect on urine output in lithium-treated rats; AVP plus PGA2 infused together evoked a near normal antidiuretic response. This antidiuretic action of PGA2 contrasts with the diuretic action reported by others. However, our infusion rates were 300-4000 times lower than those of other workers and it is suggested that PGs may have opposite actions on the kidney depending on their concentration. The effect of indomethacin (a blocker of prostaglandin synthesis) on urine flow was tested in five groups of rats on different régimes of liquid intake. Urine flow was reduced in the three groups with the highest urine volumes before treatment, and increased in the two groups with the lowest urinary volumes, again indicating that PGs may have both diuretic and antidiuretic actions.
D000818:Animals; D001127:Arginine Vasopressin / Q000494:pharmacology*; D004357:Drug Synergism; D007213:Indomethacin / Q000494:pharmacology; D007263:Infusions, Parenteral; D008094:Lithium / Q000037:antagonists & inhibitors*; D008297:Male; D011188:Potassium / Q000652:urine; D011454:Prostaglandins A / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D012964:Sodium / Q000652:urine; D014556:Urine / Q000378:metabolism; D014667:Vasopressins / Q000031:analogs & derivatives*
D011454:Prostaglandins A; D014667:Vasopressins; D001127:Arginine Vasopressin; D008094:Lithium; D012964:Sodium; D011188:Potassium; D007213:Indomethacin